Should You Follow Neil Woodford And Buy GlaxoSmithKline plc, AstraZeneca plc, Circassia Pharmaceuticals PLC, Oxford Pharmascience Group Plc And ReNeuron Group Plc?

Could GlaxoSmithKline plc (LON:GSK), AstraZeneca plc (LON:AZN), Circassia Pharmaceuticals PLC (LON:CIR), Oxford Pharmascience Group Plc (LON:OXP) and ReNeuron Group Plc (LON:RENE) be good additions to your portfolio?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Neil Woodford has been an investor in the pharmaceuticals industry for most of his long career. In a recent blog, the ace fund manager wrote: “The pharmaceuticals sector is no longer as cheap as it was but it still looks very attractive in my view, capable of delivering very attractive long-term returns”.

A whopping 34% of the CF Woodford Equity Income fund is invested in the healthcare sector, compared with the FTSE All-Share index weighting of less than 9%.

GlaxoSmithKline (LSE: GSK), AstraZeneca (LSE: AZN), Circassia Pharmaceuticals (LSE: CIR), Oxford Pharmascience (LSE: OXP) and ReNeuron (LSE: RENE) are just five of Woodford’s holdings in the sector.

FTSE 100 giants GlaxoSmithKline and AstraZeneca need little introduction. With market capitalisations of £76bn and £57bn, respectively, they are among the bluest of blue chips.

Glaxo currently trades on a forward P/E of 17.3, while Astra trades on 16.3. These earnings ratings may not appear particularly cheap, but as high dividend yields of 5.1% and 4.1% suggest, it is the prodigious cash generation of these mature companies that is the big attraction.

Glaxo and Astra are among the cornerstones of Woodford’s fund. Astra is his biggest holding, weighted at 7.8% of the portfolio, while Glaxo stands at number four with a 6.3% weighting. If you’re in the market for some solid blue chips, these two giants are certainly worth considering.

Oxford Pharmascience and ReNeuron are both capitalised at around £60m, and both companies are targeting areas of unmet medical need. Oxford Pharmascience redevelops already-approved drugs to make them better, safer and easier to take. ReNeuron is a leading, clinical-stage stem cell business.

Oxford Pharmascience is expected to post a loss before tax of £3.5m for 2014, but to swing to a £15m profit this year, giving the company a P/E of under five. ReNeuron is expected to post annual losses in the region of £10m through to its financial year ending 31 March 2016, but is forecast to post a £26m profit the following year. ReNeuron’s P/E is similar to that of Oxford Pharmascience, adjusting for ReNeuron’s later move to profitability.

Circassia has a market capitalisation of over £500m, but isn’t expected to be profitable in the near future. However, the company does have cash of £187m to absorb forecast annual losses of around £60m in 2015 and 2016.

Circassia is developing allergy treatments that build up immunity quicker than traditional remedies and without the risk of anaphylactic shocks. The company’s most advanced treatment is for cat allergy, and it has six other treatments in the pipeline.

Woodford is excited about the prospects of Circassia, Oxford Pharmascience and ReNeuron — and you may be, too, if you’re looking for higher-risk investment ideas — but it should be noted that each of these three companies has a weighting of less than 0.4% in the CF Woodford Equity Income fund.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

3 of my top FTSE 250 stocks to consider buying before April

Buying undervalued UK shares can be a great way to generate long-term wealth. Here, Royston Wild reveals a handful on…

Read more »

Ice cube tray filled with ice cubes and three loose ice cubes against dark wood.
Investing Articles

Just released: our 3 top income-focused stocks to buy before April [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »

Investing Articles

Is this the best chance to buy cheap FTSE 100 shares in a generation?

I want to buy shares when they're cheap, and sell... never, just keep taking the dividends. And the FTSE 100…

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

Could NatWest shares be 2024’s number one buy for passive income?

For those of us looking to earn some long-term passive income, how does NatWest's 7% dividend yield sound? It sounds…

Read more »

Investing Articles

£12K in savings? Here’s how I could turn that into £13K annual passive income

This Fool explains how investing a lump sum can help her build a passive income stream to enjoy in her…

Read more »

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

Here’s why Rolls-Royce shares are now set to fly over the £4 mark

Once again, Rolls-Royce shares are crushing the FTSE 100. Should I add to my holding of this stock at the…

Read more »

Investing Articles

1 under the radar FTSE 100 AI stock investors should consider buying

Our writer explains why this FTSE 100 pick could be a shrewd investment with its established experience of using AI…

Read more »

Investing Articles

Does the beaten-down Diageo share price make it a no-brainer buy?

Harvey Jones spent years waiting for the Diageo share price to look like good value, before finally buying it in…

Read more »